Last updated: August 24, 2023

Summarytoggle arrow icon

Hypertension (HTN) is a common condition that affects one in every three adults in the United States and is becoming increasingly prevalent among children. The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines define hypertension in adults as a blood pressure of ≥ 130/80 mm Hg and the Eighth Joint National Committee (JNC 8) criteria specify ≥ 140/90 mm Hg. Hypertension can be classified as either primary (essential) or secondary. Primary hypertension accounts for ∼ 90% of cases of hypertension and has no detectable cause, whereas secondary hypertension is caused by a specific underlying condition. Typical underlying conditions include renal, endocrine, and vascular diseases (e.g., renal failure, primary hyperaldosteronism, coarctation of the aorta). Clinically, hypertension is usually asymptomatic until organ damage occurs, with the brain, heart, kidneys, and/or eyes (e.g., retinopathy, myocardial infarction, stroke) most commonly affected. If present, early symptoms of hypertension may include headache, dizziness, tinnitus, and chest discomfort. Hypertension is suspected if in-office blood pressure is persistently elevated on two or more separate measurements and is confirmed with out-of-office measurement. Further diagnostic measures include assessment of cardiovascular risk, evaluation of possible target organ damage (e.g., kidney function tests), and additional tests if an underlying disease is suspected. Treatment of primary hypertension includes lifestyle changes (e.g., diet, weight loss, exercise) and pharmacotherapy. Commonly prescribed antihypertensive medications include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), thiazide diuretics, and calcium channel blockers (CCBs); pharmacological management of pediatric and pregnant patients differs, as some of these drugs are contraindicated in these patient populations. To treat secondary hypertension, the underlying cause needs to be addressed.

See also “Hypertensive crisis.”

Definitiontoggle arrow icon

  • Hypertension in adults
    • 2017 ACC/AHA: persistent systolic blood pressure (SBP) ≥ 130 mm Hg and/or diastolic blood pressure (DBP) ≥ 80 mm Hg [1]
    • 2020 International Society of Hypertension (ISH) and 2014 JNC 8: persistent SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg [2][3]
  • Hypertension in children
    • < 13 years of age: blood pressure ≥ 95th percentile or ≥ 130/80 mm Hg, whichever is lower [4]
    • ≥ 13 years of age: persistent systolic blood pressure (SBP) ≥ 130 mm Hg and/or diastolic blood pressure (DBP) ≥ 80 mm Hg [4]
  • Primary hypertension: hypertension with no identifiable cause
  • Secondary hypertension: hypertension caused by an identifiable underlying condition
  • Resistant hypertension: hypertension that remains uncontrolled (≥ 130/80 mm Hg) despite treatment with ≥ 3 antihypertensives OR requires ≥ 4 medications to be controlled [1][5][6]

Classificationtoggle arrow icon

Classification of hypertension in adults
2017 ACC/AHA guideline [1] 2014 JNC 8 guideline [2][7] 2020 ISH guideline [3]
Normal blood pressure
  • SBP < 120 mm Hg
  • AND DBP < 80 mm Hg
  • SBP < 130 mm Hg
  • AND DBP < 85 mm Hg
Elevated blood pressure
  • SBP 120–129 mm Hg
  • AND DBP < 80 mm Hg
  • SBP 120–139 mm Hg
  • OR DBP 80–89 mm Hg
  • SBP 130–139 mm Hg
  • OR DBP 85–89 mm Hg
Stage 1 hypertension
  • SBP 130–139 mm Hg
  • OR DBP 80–89 mm Hg
  • SBP 140–159 mm Hg
  • OR DBP 90–99 mm Hg
Stage 2 hypertension
  • SBP ≥ 140 mm Hg
  • OR DBP ≥ 90 mm Hg
  • SBP ≥ 160 mm Hg
  • OR DBP ≥ 100 mm Hg

Epidemiologytoggle arrow icon

  • Prevalence [1]
    • Hypertension affects between approximately one-third and one-half of adults in the US. [8][9]
    • Prevalence increases with age: Approximately 65–75% of adults develop hypertension by 65–74 years of age. [11]
    • Rates are highest in African American individuals, followed by white individuals, and lowest in Asian American and Hispanic individuals. [8][12][13][14]
    • ∼ 60–87% of overweight and ∼ 73–95% of obese patients are affected. [15]
  • Sex [1]

Epidemiological data refers to the US, unless otherwise specified.

Etiologytoggle arrow icon

Primary hypertension [1][8]

Secondary hypertension

See “Secondary hypertension.”

Clinical featurestoggle arrow icon

Since hypertension is often asymptomatic, regular screening is necessary to prevent end-organ damage.

Subtypes and variantstoggle arrow icon

White coat and masked hypertension [1]

These subtypes can be distinguished either by ambulatory blood pressure measurement (ABPM) or home blood pressure monitoring (HBPM).

Interpretation of blood pressure readings [1][16]
In-office blood pressure Out-of-office blood pressure

Sustained hypertension

  • Elevated
  • Elevated
White coat hypertension (isolated clinic hypertension)
  • Elevated
  • Normal
Masked hypertension (isolated ambulatory hypertension)
  • Normal
  • Elevated

White coat hypertension [1][16]

  • Definition: elevated blood pressure readings in a clinical setting (caused by anxiety) but normal readings when measured elsewhere
  • Diagnostics
    • Confirm true elevation of the in-office blood pressure measurements.
      • Take different blood pressure measurements several minutes apart (after the patient has had time to relax).
      • Take blood pressure measurements on several visits (at least two).
    • Consider screening using daytime ABPM (preferable) or HBPM in patients with in-office blood pressure ≥ 130/89 mm Hg and ≤ 160/100 mm Hg after a 3-month trial of lifestyle changes.
    • Diagnosis is confirmed in patients with: [1]
      • In-office readings ≥ 130/89 mm Hg and ≤ 160/100 mm Hg
      • AND out-of-office readings < 130/80 mm Hg
  • Management

In patients with white coat hypertension, the incidence of conversion to sustained hypertension is ∼ 1–5% per year. It is unclear if the risk of ASCVD is increased; this likely depends on the presence of additional risk factors. [1][16]

Hypertension that is only recorded in clinical settings in patients currently on antihypertensive medication is called white coat effect.

Masked hypertension [1][16]

Patients with masked hypertension have a similar risk of stroke, cardiovascular disease, and all-cause mortality to those with sustained hypertension. [1][16]

Isolated systolic hypertension [17][18]

Patients with isolated systolic hypertension have a high risk of renal dysfunction and cardiovascular events, e.g., myocardial infarction, stroke.

Secondary hypertensiontoggle arrow icon

Signs suggestive of secondary hypertension [1][19]

Aortic dissection is a (rare) life-threatening cause of secondary hypertension that may manifest with a blood pressure difference between the right and left arm.

Causes of secondary hypertension [1][10][10][19]

Young adults (especially women < 40 years of age) with suspected secondary hypertension should be assessed for renal artery stenosis caused by fibromuscular dysplasia.

RECENT: Renal (e.g., renal artery stenosis, glomerulonephritis), Endocrine (e.g., Cushing syndrome, hyperthyroidism, Conn syndrome), Coarctation of the aorta, Estrogen (oral contraceptives), Neurological (raised intracranial pressure, psychostimulants use), and Treatment (e.g., glucocorticoids, NSAIDs) are the causes of secondary hypertension.

Renal hypertension

Any renal disease can potentially trigger hypertension.

Endocrine hypertension

Common causes of endocrine hypertension [1]
Potential indication for further workup Typical findings
Primary hyperaldosteronism (Conn syndrome)
Hypercortisolism (Cushing syndrome)
  • TSH, ↑ free T4
Primary hyperparathyroidism
  • Typically asymptomatic
  • ↑ Serum calcium
Congenital adrenal hyperplasia

It is not necessary to stop a patient's antihypertensive medications prior to testing for primary hyperaldosteronism. [22]



Diagnosticstoggle arrow icon

Approach [1]

Screening for hypertension [8]

  • Indications
    • Annual screening [1]
    • Screening every 3–5 years: individuals 18–39 years of age with previously normal blood pressure (< 130/85 mm Hg) and no risk factors
  • Method: in-office blood pressure measurement
    • If elevated, measurements should be repeated on both arms.
    • Elevated average blood pressure on at least two readings obtained on at least two separate visits supports a diagnosis of hypertension. [1]

∼ 20% of individuals with high blood pressure are unaware they have hypertension. [23]

Diagnostic confirmation [1][8][24]

Out-of-office measurement is recommended in all individuals for confirmation of hypertension before initiating treatment.

  • Ambulatory blood pressure measurement (ABPM): preferred method
    • A device measures blood pressure at fixed intervals (e.g., every 15–30 minutes) over 12–24 hours.
    • Takes measurements while the individual is carrying out normal activities during the day and at nighttime
  • Home blood pressure monitoring (HBPM): Blood pressure is measured by the individual at periodic intervals.

Patients should be taught to measure their own blood pressure to allow for long-term monitoring and assessment of treatment.

Evaluation of patients with newly diagnosed hypertension [1][3][19]

The initial exam should focus on evaluation for signs indicating secondary hypertension and target organ damage, and the assessment of ASCVD risk. [25]

The initial evaluation should include an assessment for orthostatic hypotension (by measuring blood pressure while sitting and standing), especially in older adults. All adults ≤ 30 years of age with elevated brachial blood pressure should also have their blood pressure measured in their thigh to rule out coarctation of the aorta. [1]

Some experts recommend that all individuals with hypertension be tested for primary hyperaldosteronism at least once because of its relatively high prevalence in patients with hypertension. [5][22]

Managementtoggle arrow icon

Recommendations regarding indications for treatment and target blood pressure differ between clinical practice guidelines. The following recommendations are consistent with those in the 2017 ACC/AHA guidelines unless specified otherwise. [1][2][3][26][27]

Approach [1]

Nonpharmacological measures

  • Lifestyle measures alone may be trialed for 3–6 months in patients with: [5]
Lifestyle changes for managing hypertension [1][5][19]
Intervention (in order of effectiveness) Target Approximate SBP reduction in hypertensive patients
Weight loss (most effective measure)
  • 1 mm Hg per kg reduction in body weight in overweight individuals
Diet DASH diet
  • Diet rich in fruits, vegetables, and whole grains [28]
  • Low in saturated and trans fats
  • 11 mm Hg
Decrease dietary sodium
  • Daily sodium intake < 1500 mg [5][25][28]
  • 5–6 mm Hg
Increase dietary potassium
  • Daily potassium intake 3.5–5 g (preferably by increasing fruit and vegetable intake) [29]
  • 4–5 mm Hg
Decrease alcohol intake
  • 4 mm Hg
Exercise Aerobic [30]
  • 90–150 minutes per week [5][28]
  • 5–8 mm Hg
Dynamic resistance (e.g., weight training)
  • 90–150 minutes per week
  • 4 mm Hg
Isometric resistance (e.g., hand grip exercise)
  • Three sessions per week
  • 5 mm Hg

Smoking cessation should be advised in all patients to reduce ASCVD risk. [1]

Consider possible psychosocial factors or social determinants of health that may be contributing to the patient's high blood pressure (e.g., stress, anxiety, lack of access to fresh food) and make appropriate referrals where necessary. [5]

Increased potassium intake should not be recommended for patients with advanced CKD. [29]

Pharmacological treatmenttoggle arrow icon

Indications for antihypertensive treatment [1][2][3][31][32]

The thresholds for pharmacological treatment are controversial and vary depending on age (see “Hypertension in older adults”); the following recommendations are based on the 2017 ACC/AHA guidelines.

Initial medication [1][2][19]

Choice of initial medication should be based on the following:

  • Patient's initial blood pressure ; [3][33]
    • SBP 130–139 mm Hg or DBP 80–89 mm Hg (stage 1 hypertension): Consider initial monotherapy.
    • SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg AND an average blood pressure > 20/10 mm Hg above target
  • Additional factors to consider

To maximize medication adherence, prescribe generic medications in dosing regimens comprising as few pills as few times a day as possible (use combination pills whenever clinically appropriate), and provide a 90-day medication supply once the dosage is stable.

First-line options

First-line antihypertensive medications [1][19][25][35]
Drug class Examples Indications
Thiazide diuretics
Dihydropyridine CCBs [19]
Nondihydropyridine CCBs
  • Less commonly used

First-line medications for primary hypertension are thiazide diuretics, ACEIs, ARBs, and dihydropyridine CCBs.

Do not prescribe an ACEI and ARB together or in combination with a direct renin inhibitor. This increases the risk of hyperkalemia and renal dysfunction and does not provide additional benefit. [1][19]

Second-line options

Second-line antihypertensive medications [1][25]
Drug class Examples Indications
Beta blockers
Loop diuretics
Potassium-sparing diuretics Aldosterone antagonists
Epithelial sodium channel blockers
Direct renin inhibitors
  • Rarely used
Alpha-1 blockers
Alpha-2 agonists
  • Rarely used
Direct arteriolar vasodilators
  • Hydralazine is a treatment option in pregnant patients.

Patients with CKD or baseline potassium > 5.5 mEq/L and those who take potassium supplements or potassium-sparing drugs are at higher risk of hyperkalemia as an adverse effect from pharmacological treatment for hypertension. [1][25][28]

Do not abruptly discontinue beta blockers or alpha-2 agonists. They must be slowly tapered to avoid triggering rebound hypertension. [1]

Treatment based on comorbidities

Antihypertensive treatment by comorbidities [1]

Comorbidity Treatment recommendations

History of stroke or TIA [37]

  • Initial therapy
  • Treatment goal: blood pressure < 130/80 mm Hg in most patients [1]

Stable ischemic heart disease

CKD [28]
Asthma [40]

Do not use nondihydropyridine CCBs in patients with HFrEF because of their myocardial depressant effects. [1]

Beta blockers can mask symptoms of hypoglycemia in patients with diabetes mellitus.

Long-term management and follow-uptoggle arrow icon

General principles [1][2][5]

Goals include evaluating medication adherence, monitoring treatment and relevant laboratory studies, and adjusting medication.

  • Patients on nonpharmacological treatment alone: Follow up after 3–6 months.
    • If blood pressure is uncontrolled: Initiate pharmacological treatment.
  • Most patients initiated on pharmacological treatment: Follow up after ∼ 1 month.
    • If blood pressure is uncontrolled: Continue to escalate therapy at one-month intervals.
    • Once blood pressure is controlled: Reassess after 3–6 months and annually thereafter if blood pressure remains stable.

Laboratory studies [1][2][5]

  • Serum electrolytes
    • For most patients, check at the one-month follow-up visit.
    • Checking after ∼ 2 weeks may be reasonable in certain patients, e.g.:
  • Serum creatinine
    • Check within 2–4 weeks in patients with CKD who were started on an ACEI or ARB.
    • Discontinuation of ACEIs or ARBs is usually not necessary if creatinine increases by < 30% from baseline without concomitant hyperkalemia or fluid retention. [28]

Medication titration [1]

Therapeutic inertia (failure on the part of the physician to appropriately escalate treatment when indicated) is one possible reason for poor blood pressure control. Be sure to reassess the treatment plan at each visit. [44]

Resistant hypertensiontoggle arrow icon

Resistant hypertension affects ∼ 15% of all individuals treated for hypertension in the US. [6]

Special patient groupstoggle arrow icon

Select patient groups (e.g., children, older adults, pregnant patients) require specialized management if hypertension develops. Hypertension in children and hypertension in older adults are covered below. Hypertensive pregnancy disorders are covered in a separate article.

Hypertension in older adultstoggle arrow icon

Special considerations [32][46]

In older adults, isolated systolic hypertension is common because of age-related stiffening of the arteries. [1]

Diagnostics [1][3][46]


Nonpharmacological management [32][46]

Pharmacological therapy [1][3][32]

Hypertension in childrentoggle arrow icon

Special considerations [4][49]

Risk factors for hypertension in children [4]


Classification of hypertension in children [4][49]
Age < 13 years [4] Age ≥ 13 years [4]
Normal blood pressure
  • SBP < 120 mm Hg
  • AND DBP < 80 mm Hg
Elevated blood pressure
  • SBP 120–129 mm Hg
  • AND DBP < 80 mm Hg
Stage 1 HTN
  • SBP 130–139 mm Hg
  • OR DBP 80–89 mm Hg
Stage 2 HTN
  • BP ≥ 95th percentile + 12– 29 mm Hg
  • OR SBP ≥ 140 mm Hg
  • OR DBP ≥ 90 mm Hg
  • SBP ≥ 140 mm Hg
  • OR DBP ≥ 90 mm Hg
Acute severe hypertension
  • SBP ≥ 180 mm Hg
  • OR DBP ≥ 120 mm Hg

Screening for hypertension in children [4]

Ensure proper cuff size when measuring blood pressure; for children and adolescents with obesity, consider using an adult-sized cuff. [4]

Diagnostics for hypertension in children [4][49]

Electrocardiography is not recommended to screen for LVH because of low sensitivity in children. [4]

A complete evaluation for secondary hypertension is not necessary for hypertensive children > 6 years of age who are obese, have a family history of hypertension, and have no concerning history or physical examination findings. [4]

Management of hypertension in children [4][49]


Consider referral to a pediatric cardiologist or nephrologist for all children with a diagnosis of hypertension. [4]

Pharmacotherapy [4]

ACE inhibitors or ARBs are generally preferred for hypertensive children with diabetes, CKD, and/or proteinuria. [4]

Beta blockers are not recommended for the initial treatment of hypertension in children because of their potential adverse effects (metabolic effects such as impaired glucose tolerance and potential exacerbation of asthma) and lack of improved efficacy compared to other medications. [4]

Follow-up [4]

  • Treatment with lifestyle modifications only: office visits every 3–6 months
  • Treatment with pharmacotherapy:
    • Office visits every 4–6 weeks until blood pressure is at target, then every 3–4 months [4]
    • Periodic monitoring (e.g., every 6–12 months) for end-organ damage

Prevention [4]

Complicationstoggle arrow icon

Cardiovascular system (hypertensive vascular disease) [51][52]

Brain [51][52][53]

Kidneys [52][54]

Eyes [51][52]

Classification system according to Keith-Wagener-Barker [51]
Grade Findings Symptoms
Grade I Vessel diameter variation: arteriolar constriction and tortuosity Usually asymptomatic
Grade II Gunn sign and marked constriction of vessels and sclerosis of arterioles
Grade III Cotton wool exudates, hard exudates, retinal hemorrhage, retinal edema, macular star formation Decreased and/or blurred vision, headaches
Grade IV Papilledema, optic atrophy

Local treatment of retinopathy is not possible, therefore, systemic reduction of blood pressure is critical.

We list the most important complications. The selection is not exhaustive.

Related One-Minute Telegramtoggle arrow icon

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

Referencestoggle arrow icon

  1. Whelton, PK, Carey, RM et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2017; 71 (6): p.e13–e115.doi: 10.1161/hyp.0000000000000065 . | Open in Read by QxMD
  2. James PA, Oparil S, Carter BL et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311 (5): p.507-520.doi: 10.1001/jama.2013.284427 . | Open in Read by QxMD
  3. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines.. Hypertension (Dallas, Tex. : 1979). 2020; 75 (6): p.1334-1357.doi: 10.1161/HYPERTENSIONAHA.120.15026 . | Open in Read by QxMD
  4. Flynn et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140 (3).doi: 10.1542/peds.2017-1904 . | Open in Read by QxMD
  5. Carey RM, Wright JT, Taler SJ, Whelton PK. Guideline-Driven Management of Hypertension. Circ Res. 2021; 128 (7): p.827-846.doi: 10.1161/circresaha.121.318083 . | Open in Read by QxMD
  6. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018; 72 (5).doi: 10.1161/hyp.0000000000000084 . | Open in Read by QxMD
  7. Krist AH, Davidson KW, et al. Screening for Hypertension in Adults. JAMA. 2021; 325 (16): p.1650.doi: 10.1001/jama.2021.4987 . | Open in Read by QxMD
  8. Hernandez-Vila E. A Review of the JNC 8 Blood Pressure Guideline. Tex Heart Inst J. 2015; 42 (3): p.226-228.doi: 10.14503/thij-15-5067 . | Open in Read by QxMD
  9. Charles L, Triscott J, Dobbs B. Secondary Hypertension: Discovering the Underlying Cause. Am Fam Physician. 2017; 96 (7): p.453-461.
  10. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.. Circulation. 2001; 103 (9): p.1245-9.doi: 10.1161/01.cir.103.9.1245 . | Open in Read by QxMD
  11. Williams SK, Ravenell J, Seyedali S, Nayef H, Ogedegbe G. Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines. Prog Cardiovasc Dis. 2016; 59 (3): p.282-288.doi: 10.1016/j.pcad.2016.09.004 . | Open in Read by QxMD
  12. Cuevas AG, Williams DR, Albert MA. Psychosocial Factors and Hypertension. Cardiol Clin. 2017; 35 (2): p.223-230.doi: 10.1016/j.ccl.2016.12.004 . | Open in Read by QxMD
  13. Carnethon MR, Pu J, Howard G, et al. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation. 2017; 136 (21).doi: 10.1161/cir.0000000000000534 . | Open in Read by QxMD
  14. Bramlage P, Pittrow D, Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004; 17 (10): p.904-910.doi: 10.1016/j.amjhyper.2004.05.017 . | Open in Read by QxMD
  15. Kario K, Thijs L, Staessen JA. Blood Pressure Measurement and Treatment Decisions. Circ Res. 2019; 124 (7): p.990-1008.doi: 10.1161/circresaha.118.313219 . | Open in Read by QxMD
  16. Chobanian AV. Isolated Systolic Hypertension in the Elderly. N Engl J Med. 2007; 357 (8): p.789-796.doi: 10.1056/nejmcp071137 . | Open in Read by QxMD
  17. Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT. Am J Med. 2016; 129 (12): p.1251-1258.doi: 10.1016/j.amjmed.2016.08.032 . | Open in Read by QxMD
  18. Muntner P, Hardy ST, Fine LJ, et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020; 324 (12): p.1190.doi: 10.1001/jama.2020.14545 . | Open in Read by QxMD
  19. Shimbo D, Artinian NT, Basile JN, et al. Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. Circulation. 2020; 142 (4).doi: 10.1161/cir.0000000000000803 . | Open in Read by QxMD
  20. Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018; 4 (1).doi: 10.1038/nrdp.2018.14 . | Open in Read by QxMD
  21. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): p.3021-3104.doi: 10.1093/eurheartj/ehy339 . | Open in Read by QxMD
  22. Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2018; 285 (2): p.126-148.doi: 10.1111/joim.12831 . | Open in Read by QxMD
  23. Overview of Hypertension. Updated: July 1, 2016. Accessed: February 20, 2017.
  24. What Are the Signs, Symptoms, and Complications of High Blood Pressure?. Updated: September 10, 2015. Accessed: February 20, 2017.
  25. Hemphill JC, Greenberg SM, Anderson CS et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015; 46 (7).doi: 10.1161/STR.0000000000000069 . | Open in Read by QxMD
  26. Renal Artery Stenosis and Occlusion. Updated: July 1, 2016. Accessed: February 20, 2017.
  27. Lusco MA, Najafian B, Alpers CE, Fogo AB. AJKD Atlas of Renal Pathology: Arterionephrosclerosis. American Journal of Kidney Diseases. 2016; 67 (4): p.e21-e22.doi: 10.1053/j.ajkd.2016.02.035 . | Open in Read by QxMD
  28. Riley M, Hernandez AK, Kuznia AL. High Blood Pressure in Children and Adolescents. Am Fam Physician. 2018; 98 (8): p.486-494.
  29. Klein DA, et al. Screening and Counseling Adolescents and Young Adults: A Framework for Comprehensive Care. Am Fam Physician. 2020; 101 (3): p.147-158.
  30. Bakris G. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019; 124 (7): p.969-971.doi: 10.1161/circresaha.118.314664 . | Open in Read by QxMD
  31. Flack JM, Calhoun D. The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. Am J Hypertens. 2019; 32 (8): p.705-708.doi: 10.1093/ajh/hpz092 . | Open in Read by QxMD
  32. Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99 (3): p.S1-S87.doi: 10.1016/j.kint.2020.11.003 . | Open in Read by QxMD
  33. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. American Journal of Kidney Diseases. 2020; 76 (3): p.S1-S107.doi: 10.1053/j.ajkd.2020.05.006 . | Open in Read by QxMD
  34. Boonyasai RT, Rakotz MK, Lubomski LH, et al. Measure accurately, Act rapidly, and Partner with patients: An intuitive and practical three-part framework to guide efforts to improve hypertension control. J Clin Hypertens (Greenwich). 2017; 19 (7): p.684-694.doi: 10.1111/jch.12995 . | Open in Read by QxMD
  35. Taler SJ. Initial Treatment of Hypertension. N Engl J Med. 2018; 378 (7): p.636-644.doi: 10.1056/nejmcp1613481 . | Open in Read by QxMD
  36. Dunlap B, Kantha Shelke K, Salem SA, Keith LG. Folic acid and human reproduction - ten important issues for clinicians. J Exp Clin Assist Reprod. 2011; 8: p.2.
  37. MacDonald TM, Williams B, Webb DJ, et al. Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double‐Blind Randomized Controlled Trial. J Am Heart Assoc. 2017; 6 (11).doi: 10.1161/jaha.117.006986 . | Open in Read by QxMD
  38. Smith DK, Lennon RP, Carlsgaard PB. Managing Hypertension Using Combination Therapy.. Am Fam Physician. 2020; 101 (6): p.341-349.
  39. Egan BM, Sutherland SE, Rakotz M, et al. Improving Hypertension Control in Primary Care With the Measure Accurately, Act Rapidly, and Partner With Patients Protocol. Hypertension. 2018; 72 (6): p.1320-1327.doi: 10.1161/hypertensionaha.118.11558 . | Open in Read by QxMD
  40. Vongpatanasin W. Resistant Hypertension. JAMA. 2014; 311 (21): p.2216.doi: 10.1001/jama.2014.5180 . | Open in Read by QxMD
  41. Guidelines Developed by External Organizations Not Endorsed by the AAFP. . Accessed: June 7, 2021.
  42. Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166 (6): p.430.doi: 10.7326/m16-1785 . | Open in Read by QxMD
  43. Whelton PK, Williams B. The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines. JAMA. 2018; 320 (17): p.1749.doi: 10.1001/jama.2018.16755 . | Open in Read by QxMD
  44. Westby A, Okah E, Ricco J. Race-Based Treatment Decisions Perpetuate Structural Racism. Am Fam Physician. 2020; 102 (3): p.136-137.
  45. De Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40 (9): p.1273-1284.doi: 10.2337/dci17-0026 . | Open in Read by QxMD
  46. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021.doi: 10.1161/str.0000000000000375 . | Open in Read by QxMD
  47. American Diabetes Associaton. 11. Microvascular Complications and Foot Care:Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020; 44 (Supplement 1): p.S151-S167.doi: 10.2337/dc21-s011 . | Open in Read by QxMD
  48. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020; 44 (Supplement 1): p.S125-S150.doi: 10.2337/dc21-s010 . | Open in Read by QxMD
  49. Christiansen SC, Zuraw BL. Treatment of Hypertension in Patients with Asthma. N Engl J Med. 2019; 381 (11): p.1046-1057.doi: 10.1056/nejmra1800345 . | Open in Read by QxMD
  50. Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2019; 43 (2): p.99-107.doi: 10.1002/clc.23303 . | Open in Read by QxMD
  51. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019; 124 (7): p.1045-1060.doi: 10.1161/circresaha.118.313236 . | Open in Read by QxMD
  52. Coles S, Fisher L, Lin KW, Lyon C, Vosooney AA, Bird MD. Blood Pressure Targets in Adults With Hypertension: A Clinical Practice Guideline From the AAFP. Am Fam Physician. 2022; 106 (6): p.Online.
  53. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.. JAMA. 2003; 289 (19): p.2560-72.doi: 10.1001/jama.289.19.2560 . | Open in Read by QxMD
  54. Ruby ST. Unilateral Renal Artery Stenosis Seen Initially as Severe and Symptomatic Hypokalemia. Arch Surg. 1993; 128 (3): p.346-8.doi: 10.1001/archsurg.1993.01420150106019 . | Open in Read by QxMD
  55. Singh PK, Rajput R, Banerjee S, Garg K. Unilateral renal artery stenosis presenting as acute flaccid paralysis: a rare presentation. BMJ Case Reports. 2018: p.bcr-2018-225889.doi: 10.1136/bcr-2018-225889 . | Open in Read by QxMD

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer